ASIA PACIFIC ALOPECIA TREATMENT MARKET ANALYSIS
Asia Pacific Alopecia Treatment Market: Key Developments
On March 18, 2023, Concert Pharmaceuticals, which was acquired by Sun Pharmaceutical Industries Limited, pharmaceutical company in India, announced that it will report data from its Phase 3 clinical trial THRIVE-AA2. The presentation will highlight the results of the THRIVE-AA2 study, which evaluated the oral investigational drug deruxolitinib in adult patients with moderate to severe alopecia areata.
On June 13, 2022, Eli Lilly and Company and Incyte, Delaware-based drug discovery and development company, announced that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT (baricitinib), a once-daily pill, as the first systemic drug for the treatment of alopecia areata (AA) in adults, available as 4 mg, 2 mg and 1 mg tablets. The recommended dose of OLUMIANT is 2 mg/day, which can be increased to 4 mg/day if the response is inadequate in patients with near-complete or complete scalp alopecia with or without significant hair loss of eyelashes or eyebrows, consider treatment with 4 mg daily.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :